STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Clinical trial NCT04878432 · TERMINATED

Trial details

NCT number: NCT04878432
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome (MDS)

Start date: 2022-03-17
Primary completion: 2023-10-26
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.